Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine + Cyclophosphamide in Refractory Pediatric Tumors
NCT00180947Phase 2Unknown
- Sponsor
- Gustave Roussy
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and cyclophosphamide in rhabdomyosarcoma (RMS), soft tissue sarcoma (STS), Ewing sarcoma and 3 more, sponsored by Gustave Roussy. Primary endpoint: Antitumor activity of Vinorelbine and oral Cyclofosfamide association. Status: unknown.
02
Drugs
vinorelbinecyclophosphamide
03
Conditions
rhabdomyosarcoma (RMS)soft tissue sarcoma (STS)Ewing sarcomaosteosarcoma (OS)neuroblastoma
Beyond the preview
Go deeper on NCT00180947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00180947.